摘要
类风湿性关节炎(RA),一种以慢性关节炎症和持续性滑膜细胞浸润为特征的自身免疫性疾病,研究表明抗环瓜氨酸肽抗体(ACPA)阳性RA患者的预后更差。阿巴西普是一种通过阻断T细胞激活的生物类抗风湿药物(bDMARD),相较于ACPA阴性患者,对ACPA阳性患者有着更好的缓解作用,其作用机制及其在ACPA阳性患者中的临床疗效与安全性也备受关注。本文通过对阿巴西普作用机制及其对ACPA阳性患者的疗效和安全性进行综述,以期为临床治疗该病以及未来更进一步的研究提供参考。
Rheumatoid arthritis(RA)is an autoimmune disease characterized by chronic joint inflammation and persistent synovial cell infiltration.Studies have shown that anti-cyclic citrullinated peptide antibody(ACPA)positive RA patients have a worse prognosis.Abbasip is a biological disease modifying antirheumatic drugs(bDMARD)that blocks T cell activation.Compared with ACPA negative patients,it has a better remission effect on ACPA positive patients.Its mechanism of action and its clinical efficacy and safety in ACPA positive patients have also attracted much attention.This article reviews the mechanism of abasip and its efficacy and safety in ACPA-positive patients,in order to provide reference for clinical treatment and further research in the future.
作者
黄倩
李涛
谢艳
廖霞
张全波
青玉凤
HUANG Qian;LI Tao;XIE Yan;LIAO Xia;ZHANG Quan-bo;QING Yu-feng(Department of Geriatrics,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan,China;Department of Rheumatology and Immunology,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan,China)
出处
《医学信息》
2023年第9期168-173,共6页
Journal of Medical Information
关键词
类风湿关节炎
抗环瓜氨酸肽抗体
T细胞
Rheumatoid arthritis
Anti-cyclic citrullinated peptide antibody
T cell
